Research indicates that common respiratory illnesses, including COVID-19 and influenza, can activate dormant cancer cells in the lungs of breast cancer survivors, potentially leading to the formation of new metastases. This significant discovery was made by scientists from the Universities of Colorado, Utrecht, and Montefiore Medical Center, with their findings prominently published in the esteemed scientific journal Nature.
Experiments on laboratory mice confirmed that viral infection in the lungs triggers the activation of previously inactive tumor cells. Within a mere few days, these cells begin to divide rapidly, and new metastatic foci emerge within two weeks. A critical factor in this aggressive process is interleukin-6, an inflammatory protein released by the immune system in response to a viral threat.
This risk extends beyond animal models, as two independent studies based on extensive human data have corroborated these findings. An analysis of data from the United Kingdom revealed that cancer survivors who contracted COVID-19 had double the risk of dying from cancer-related causes compared to those who did not. Similarly, in the United States, women with breast cancer experienced an almost 50 percent increase in the likelihood of developing lung metastases after a coronavirus infection.
Ultimately, this research underscores that viral infections can pose a significant and hidden threat to patients in remission. This groundbreaking discovery opens new avenues for developing crucial preventive strategies, including enhanced vaccination efforts and the strategic use of immunomodulating agents to control inflammation and potentially avert cancer relapse.
